Skip to content
ESPT
MARKETS / NASDAQ / Health care / Pharmaceuticals / BMRN
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Biomarin Pharmaceutical Inc. BMRN

18 fiscal years on record · USD · FY2025 reported · SEC filings only
$3.2B
▲ 12.9% YoY
$348.9M
▼ 18.3% YoY
$725.0M
▲ 48.7% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

BioMarin manufactures the active pharmaceutical ingredients for ALDURAZYME, NAGLAZYME, PALYNZIQ and VOXZOGO at its production facilities in Novato, California. It also manufactures the active pharmaceutical ingredient for BRINEURA and VIMIZIM at its manufacturing facility in Shanbally, Cork, Ireland. As of December 31, 2025, the company had 3,221 employees worldwide, of whom 1,518 were in operations, 692 were in research and development, 495 were in sales and marketing and 516 were in administration. During 2025, 37% of the company's net product revenue was generated by three customers. The company's commercial organization is structured around two business units, Skeletal Conditions (VOXZOGO) and Enzyme Therapies, which support its product lines directly in the U.S., Europe, South America and certain other significant markets. The company, based in San Rafael, California, was founded in 1997. It was incorporated in Delaware in October 1996.

Written from the business description in BioMarin Pharmaceutical Inc's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 3.2B
Revenue, FY2025 · full 18-year series below
Revenue $B Net income $B
FY2025 · Revenue 3.2 · Net income 0.3
1.50B3.00B-0.25B-0.50B
2008201120142017202020232025
Compound annual growth
+15.4%
+11.6%
+13.7%
+15.4%
+35.1%
−16.4%
+3.6%
+33.9%
−16.7%
+0.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +11.6% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

11 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 12.7% · Net 10.8%
20%40%-20%-40%-60%
200820162025
ROE
FY2025 · ROE 5.9%
10%20%30%-10%-20%
200820162025
Three returns, three denominators.
Gross margin77.7%
Operating margin12.7%
Net margin10.8%
EBITDAUSD 489.0M

Each USD of equity produced 6 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 725.0
300M600M-200M-400M
200820162025
Net buybacks $M Dividends $M
FY2022 · Dividends · · Net buybacks 0.0
20M40M
20182019202020212022
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 7.6B
EquityUSD 6.1B
CashUSD 1.3B
Current ratio5.21×

Equity funds 80% of total assets.

The 18-year record

18 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
BMRN, 18-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011201020092008
Revenue $B3.22.92.42.11.81.91.71.51.31.10.90.70.50.50.40.40.30.3
Operating income $B0.40.50.20.2−0.1−0.0−0.1−0.1−0.0−0.8−0.1−0.1−0.2−0.1−0.00.00.00.0
EBITDA $B0.50.60.30.30.00.10.0−0.00.1−0.7−0.1−0.0−0.1−0.1−0.00.00.0◌
Income tax $B0.10.10.00.0−0.0−0.9−0.1−0.10.1−0.20.00.0−0.0−0.00.0−0.20.00.0
Net income $B0.30.40.20.1−0.10.9−0.0−0.1−0.1−0.6−0.2−0.1−0.2−0.1−0.10.2−0.00.0
Free cash flow $B0.70.50.10.10.2−0.0−0.1−0.1−0.2−0.4−0.4−0.2−0.1−0.0−0.1−0.0−0.0−0.1
EPS, diluted $1.802.210.870.75−0.354.50−0.13−0.44−0.67−3.81−1.07−0.92−1.28−0.95−0.481.730.000.29
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————————————
ROE %5.98.03.53.2−1.523.6−0.8−2.7−4.2−24.4−8.7−9.3−15.0−12.8−7.239.6−0.211.1
Shares out B0.190.190.190.190.180.180.180.180.180.170.160.150.140.130.110.110.10◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 69 reconciliationsAUDITED

Reconciled in 18 of the 18 fiscal years we could check. Four checks were skipped: the balance sheet is not tagged before 2009. One check was skipped: EPS is not tagged before 2008. One check was skipped: revenue is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2008

Share this section

Download image